HOMEPRODUCTSCOMPANYCONTACTFAQResearchDictionaryPharmaSign Up FREE or Login

LDL-apheresis accelerates the recovery of nonarteritic acute anterior ischemic optic neuropathy.

Abstract
Nonarteritic acute anterior ischemic optic neuropathy (NAION) is a disabling disease which impairs visual function. It is presumed to result from disturbances of microcirculation in the anterior portion of the optic nerve head due to hemodynamic factors derived from excessive blood viscosity, or restriction of the vasal lumen in hypertensive, hypercholesterolemic, diabetic patients. We aimed to determine whether acute reduction of plasma fibrinogen and serum low-density lipoprotein (LDL) cholesterol is effective for treatment of NAION. We recruited 11 patients (7 females, 4 males) with a mean age of 57.2 +/- 19.6 years. All except one of them presented risk factors for atherosclerosis. The mean values of LDL-cholesterol and fibrinogen before treatment were 144 +/- 32 mg/dL and 341 +/- 80 mg/dL, respectively. All were treated with standard therapy (prednisone, salicylate, pentoxiphyllin) and underwent three sessions of LDL-apheresis (HELP system-B Braun) that can reduce plasma LDL-cholesterol and fibrinogen by more than 50% in a very short time. In all patients we observed a drastic reduction of LDL cholesterol and fibrinogen and a clear improvement in the visual functional data. In fact, mean values of corrected vision increased from 3.7/10 +/- 3/10 to 7.9/10 +/- 2.2/10 (P = 0.002) after the third session, while the scotomatous portion of the visual field regressed after the first session, and in 5 patients further regressed after the third session. This improvement had remained stable after 3 months. Thanks to it's effect of antagonizing hemorheologic disorders of the ocular microcirculation, fibrinogen/LDL-apheresis seems to be an efficacious treatment of NAION.
AuthorsAlfonso Ramunni, Giovanni Giancipoli, Silvana Guerriero, Lucia Lapenna, Angelo Saracino, Maria Teresa Saliani, Antonio Capurso, Carlo Sborgia, Pasquale Coratelli
JournalTherapeutic apheresis and dialysis : official peer-reviewed journal of the International Society for Apheresis, the Japanese Society for Apheresis, the Japanese Society for Dialysis Therapy (Ther Apher Dial) Vol. 9 Issue 1 Pg. 53-8 (Feb 2005) ISSN: 1744-9979 [Print] Australia
PMID15828907 (Publication Type: Journal Article)
Chemical References
  • Cholesterol, LDL
  • Salicylates
  • Fibrinogen
  • Simvastatin
  • Prednisone
Topics
  • Blood Component Removal
  • Cholesterol, LDL (blood)
  • Female
  • Fibrinogen (metabolism)
  • Humans
  • Male
  • Microcirculation
  • Middle Aged
  • Optic Nerve (blood supply)
  • Optic Neuropathy, Ischemic (blood, therapy)
  • Prednisone (therapeutic use)
  • Salicylates (therapeutic use)
  • Simvastatin (therapeutic use)
  • Visual Acuity

Join CureHunter, for free Research Interface BASIC access!

Take advantage of free CureHunter research engine access to explore the best drug and treatment options for any disease. Find out why thousands of doctors, pharma researchers and patient activists around the world use CureHunter every day.
Realize the full power of the drug-disease research graph!


Choose Username:
Email:
Password:
Verify Password:
Enter Code Shown: